AnaptysBio announced its rosnilimab Phase 2 ulcerative colitis trial failed to meet primary and key secondary endpoints; the company will discontinue the UC program and redirect resources toward rheumatoid arthritis and other priorities. Anaptys said rosnilimab was safe and well tolerated but ineffective in the UC cohorts, and the decision saves roughly $10 million in near‑term costs. Separately, Neurocrine disclosed that its NBI‑1070770 mid‑stage study in major depressive disorder did not separate from placebo. The company said it will continue to analyze the dataset to determine next steps for the program while emphasizing stronger late‑stage prospects elsewhere in its pipeline. Both results underscore the persistent clinical risk in CNS and immunology drug development.